TY - JOUR
T1 - Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
AU - Gisselbrecht, C.
AU - Bethge, W.
AU - Duarte, R. F.
AU - Gianni, A. M.
AU - Glass, B.
AU - Haioun, C.
AU - Martinelli, G.
AU - Nagler, A.
AU - Pettengell, R.
AU - Sureda, A.
AU - Tilly, H.
AU - Wilson, K.
PY - 2007/12
Y1 - 2007/12
N2 - Haematopoietic SCT is currently considered a therapeutic option mainly in relapsed or refractory non-Hodgkin's lymphoma (NHL) owing to high post-transplantation relapse rates and significant toxicity of conventional myeloablative conditioning for allogeneic SCT. Radiolabelled immunotherapy combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, and is a promising advance in the treatment of malignant lymphomas. It is now under investigation as a component of conditioning prior to SCT, with the aim of improving outcomes following SCT without increasing the toxicity of high-dose chemotherapy pre-transplant conditioning. An expert panel met at a European workshop in November 2006 to review the latest data on radiolabelled immunotherapy in the transplant setting, and its potential future directions, with a focus on 90Y-ibritumomab tiuxetan. They reviewed data on the combination of standard/high/escalating dose 90Y-ibritumomab tiuxetan with high-dose chemotherapy, and high/escalating dose 90Y-ibritumomab tiuxetan as the sole myeloablative agent, prior to autologous SCT, and also 90Y- ibritumomab tiuxetan as a component of reduced intensity conditioning prior to allogeneic SCT. The preliminary data are highly promising in terms of conditioning tolerability and patient outcomes following transplant; further phase II studies are now needed to consolidate these data and to investigate specific patient populations and NHL subtypes.
AB - Haematopoietic SCT is currently considered a therapeutic option mainly in relapsed or refractory non-Hodgkin's lymphoma (NHL) owing to high post-transplantation relapse rates and significant toxicity of conventional myeloablative conditioning for allogeneic SCT. Radiolabelled immunotherapy combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, and is a promising advance in the treatment of malignant lymphomas. It is now under investigation as a component of conditioning prior to SCT, with the aim of improving outcomes following SCT without increasing the toxicity of high-dose chemotherapy pre-transplant conditioning. An expert panel met at a European workshop in November 2006 to review the latest data on radiolabelled immunotherapy in the transplant setting, and its potential future directions, with a focus on 90Y-ibritumomab tiuxetan. They reviewed data on the combination of standard/high/escalating dose 90Y-ibritumomab tiuxetan with high-dose chemotherapy, and high/escalating dose 90Y-ibritumomab tiuxetan as the sole myeloablative agent, prior to autologous SCT, and also 90Y- ibritumomab tiuxetan as a component of reduced intensity conditioning prior to allogeneic SCT. The preliminary data are highly promising in terms of conditioning tolerability and patient outcomes following transplant; further phase II studies are now needed to consolidate these data and to investigate specific patient populations and NHL subtypes.
UR - http://www.scopus.com/inward/record.url?scp=36349020774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36349020774&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1705868
DO - 10.1038/sj.bmt.1705868
M3 - Article
C2 - 17922042
AN - SCOPUS:36349020774
VL - 40
SP - 1007
EP - 1017
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 11
ER -